| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5436272 | ABBOTT | Treatment of obesity |
Jul, 2012
(11 years ago) | |
|
US5436272 (Pediatric) | ABBOTT | Treatment of obesity |
Jan, 2013
(11 years ago) | |
Meridia is owned by Abbott.
Meridia contains Sibutramine Hydrochloride.
Meridia has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Meridia are:
- US5436272
- US5436272*PED
Meridia was authorised for market use on 22 November, 1997.
Meridia is available in capsule;oral dosage forms.
Meridia can be used as treatment of obesity.
The generics of Meridia are possible to be released after 25 January, 2013.
Drugs and Companies using SIBUTRAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 November, 1997
Treatment: Treatment of obesity
Dosage: CAPSULE;ORAL
How can I launch a generic of MERIDIA before it's drug patent expiration?
More Information on Dosage
MERIDIA family patents
